StockNews.com Begins Coverage on Can-Fite BioPharma (NYSE:CANF)
Equities researchers at StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF – Get Free Report) in a note issued to investors on Tuesday. The firm set a “sell” rating on the stock. Several other analysts also recently issued reports on CANF. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on […]
Equities researchers at StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF – Get Free Report) in a note issued to investors on Tuesday. The firm set a “sell” rating on the stock. Several other analysts also recently issued reports on CANF. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on […]